1-13 of 13
Authors: Robbie Majzner
Journal Article
IMMU-60. MYELOID POPULATIONS MODULATE GD2 CAR T CELL ACTIVITY IN DIFFUSE MIDLINE GLIOMA Free
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii166, https://doi.org/10.1093/neuonc/noae165.0652
Published: 11 November 2024
Journal Article
RBIO-06. COMBINING FLASH RADIOTHERAPY WITH GD2-CAR T CELL IMMUNOTHERAPY IN DIFFUSE INTRINSIC PONTINE GLIOMA Free
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v257, https://doi.org/10.1093/neuonc/noad179.0987
Published: 10 November 2023
Journal Article
IMMU-05. TUMOR INFLAMMATION-ASSOCIATED NEUROTOXICITY (TIAN): A TOXICITY SYNDROME IN PATIENTS TREATED WITH IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS Open Access
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i50, https://doi.org/10.1093/neuonc/noad073.192
Published: 12 June 2023
Journal Article
DIPG-15. Major tumor regressions in H3K27M-mutated diffuse midline glioma (DMG) following sequential intravenous (IV) and intracerebroventricular (ICV) delivery of GD2-CAR T-cells Open Access
Neuro-Oncology, Volume 24, Issue Supplement_1, June 2022, Pages i20–i21, https://doi.org/10.1093/neuonc/noac079.072
Published: 03 June 2022
Journal Article
EPCT-14. GD2 CAR T-CELLS MEDIATE CLINICAL ACTIVITY AND MANAGEABLE TOXICITY IN CHILDREN AND YOUNG ADULTS WITH H3K27M-MUTATED DIPG AND SPINAL CORD DMG Open Access
Neuro-Oncology, Volume 23, Issue Supplement_1, June 2021, Pages i49–i50, https://doi.org/10.1093/neuonc/noab090.200
Published: 01 June 2021
Journal Article
OMIC-11. SINGLE CELL RNA SEQUENCING FROM THE CSF OF SUBJECTS WITH H3K27M+ DIPG/DMG TREATED WITH GD2 CAR T-CELLULAR THERAPY Open Access
Neuro-Oncology, Volume 23, Issue Supplement_1, June 2021, Page i39, https://doi.org/10.1093/neuonc/noab090.158
Published: 01 June 2021
Journal Article
IMMU-55. GD2 IS A MACROPHAGE CHECKPOINT MOLECULE AND COMBINED GD2/CD47 BLOCKADE RESULTS IN SYNERGISTIC EFFECTS AGAINST GD2 POSITIVE MALIGNANCIES Free
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii116, https://doi.org/10.1093/neuonc/noaa215.484
Published: 09 November 2020
Journal Article
IMMU-09. LOCALLY ADMINISTERED CAR T CELLS DEMONSTRATE MOST FAVORABLE ROUTE OF ADMINISTRATION IN A MODEL OF ATRT Free
Neuro-Oncology, Volume 21, Issue Supplement_2, April 2019, Pages ii94–ii95, https://doi.org/10.1093/neuonc/noz036.130
Published: 23 April 2019
Journal Article
ATRT-25. CHECKPOINT MOLECULE B7-H3 IS HIGHLY EXPRESSED ON ATYPICAL RHABDOID TERATOID TUMOR (ATRT) AND IS A PROMISING CANDIDATE FOR CAR T CELL THERAPY Free
Neuro-Oncology, Volume 20, Issue suppl_2, June 2018, Page i33, https://doi.org/10.1093/neuonc/noy059.023
Published: 22 June 2018
Journal Article
DIPG-36. ANTI-GD2 CHIMERIC ANTIGEN RECEPTOR T CELLS AS A POTENT IMMUNOTHERAPY REGIMEN IN XENOGRAFT MODELS OF HISTONE 3 K27M MUTANT DIFFUSE MIDLINE GLIOMA Free
Neuro-Oncology, Volume 20, Issue suppl_2, June 2018, Page i56, https://doi.org/10.1093/neuonc/noy059.129
Published: 22 June 2018
Journal Article
PDTM-39. GD2-DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELLS AS A POTENT IMMUNOTHERAPY REGIMEN IN XENOGRAFT MODELS OF DIFFUSE INTRINSIC PONTINE GLIOMA Free
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Page vi198, https://doi.org/10.1093/neuonc/nox168.802
Published: 06 November 2017
Journal Article
IMMU-45. CHECKPOINT MOLECULE B7-H3 IS HIGHLY EXPRESSED ON MEDULLOBLASTOMA AND PROVES TO BE A PROMISING CANDIDATE FOR CAR T CELL IMMUNOTHERAPY Free
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Page vi122, https://doi.org/10.1093/neuonc/nox168.503
Published: 06 November 2017
Journal Article
IMMU-07. CHECKPOINT MOLECULE B7-H3 IS HIGHLY EXPRESSED ON MEDULLOBLASTOMA AND PROVES TO BE A PROMISING CANDIDATE FOR CAR T CELL IMMUNOTHERAPY Free
Neuro-Oncology, Volume 19, Issue suppl_4, June 2017, Pages iv28–iv29, https://doi.org/10.1093/neuonc/nox083.117
Published: 31 May 2017
